IN2012DN03128A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03128A IN2012DN03128A IN3128DEN2012A IN2012DN03128A IN 2012DN03128 A IN2012DN03128 A IN 2012DN03128A IN 3128DEN2012 A IN3128DEN2012 A IN 3128DEN2012A IN 2012DN03128 A IN2012DN03128 A IN 2012DN03128A
- Authority
- IN
- India
- Prior art keywords
- compositions
- eye
- active ingredient
- treatment
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001335 aliphatic alkanes Chemical class 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000003120 macrolide antibiotic agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09015423A EP2335735A1 (en) | 2009-12-14 | 2009-12-14 | Pharmaceutical composition for treatment of dry eye syndrome |
| PCT/EP2010/069495 WO2011073134A1 (en) | 2009-12-14 | 2010-12-13 | Pharmaceutical composition for treatment of dry eye syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03128A true IN2012DN03128A (enExample) | 2015-09-18 |
Family
ID=41731659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3128DEN2012 IN2012DN03128A (enExample) | 2009-12-14 | 2010-12-13 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8614178B2 (enExample) |
| EP (2) | EP2335735A1 (enExample) |
| JP (5) | JP5663595B2 (enExample) |
| KR (2) | KR101722039B1 (enExample) |
| CN (1) | CN102652022B (enExample) |
| AU (1) | AU2010333039B2 (enExample) |
| BR (3) | BR122020020872B1 (enExample) |
| CA (2) | CA2776860C (enExample) |
| DK (1) | DK2512515T3 (enExample) |
| ES (1) | ES2449308T3 (enExample) |
| IN (1) | IN2012DN03128A (enExample) |
| MX (1) | MX2012006720A (enExample) |
| PL (1) | PL2512515T3 (enExample) |
| PT (1) | PT2512515E (enExample) |
| WO (1) | WO2011073134A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2437684B1 (en) | 2009-06-03 | 2022-06-15 | ForSight Vision5, Inc. | Anterior segment drug delivery |
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| CN103561724B (zh) | 2011-05-25 | 2016-06-29 | 诺瓦利克有限责任公司 | 给药给甲的药物组合物 |
| JP6039145B2 (ja) | 2011-05-25 | 2016-12-07 | ノバリック ゲーエムベーハー | 半フッ化アルカンを基礎にした局所薬学的組成物 |
| PT2806886T (pt) | 2012-01-23 | 2017-03-24 | Novaliq Gmbh | Composições de proteínas estabilizadas baseadas em alcanos semifluorados |
| MX363182B (es) * | 2012-09-12 | 2019-03-13 | Novaliq Gmbh | Composiciones que comprenden mezclas de alcanos semifluorados. |
| EP2895144B1 (en) | 2012-09-12 | 2017-01-11 | Novaliq GmbH | Semifluorinated alkane compositions |
| PL2708228T3 (pl) | 2012-09-12 | 2018-11-30 | Novaliq Gmbh | Kompozycje do przemywania oczu |
| EP2730291A1 (en) * | 2012-11-09 | 2014-05-14 | Fluoron Gmbh | Internal Tamponade Composition |
| US10172789B2 (en) | 2013-01-24 | 2019-01-08 | Palvella Therapeutics Llc | Compositions for transdermal delivery of mTOR inhibitors |
| JP6304475B2 (ja) * | 2013-01-31 | 2018-04-04 | ロート製薬株式会社 | 点眼剤 |
| TWI623313B (zh) * | 2013-03-13 | 2018-05-11 | Santen Pharmaceutical Co Ltd | 瞼板腺功能障礙之治療劑 |
| DK3024484T3 (en) | 2013-07-23 | 2018-10-08 | Novaliq Gmbh | STABILIZED ANTIBODY COMPOSITIONS |
| US20160243291A1 (en) * | 2013-10-15 | 2016-08-25 | Forsight Vision5, Inc. | Formulations and Methods for Increasing or Reducing Mucus |
| US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
| US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
| EP3283004A4 (en) | 2015-04-13 | 2018-12-05 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| US11013403B2 (en) * | 2015-09-29 | 2021-05-25 | The Regents Of The University Of California | Methods of diagnosing diseases of mucosal surfaces |
| US20170087100A1 (en) | 2015-09-30 | 2017-03-30 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| EP3722274B1 (en) * | 2015-09-30 | 2023-06-07 | Novaliq GmbH | 2-perfluorobutyl pentane for ophthalmic administration |
| DK3442480T3 (da) | 2016-06-23 | 2020-01-13 | Novaliq Gmbh | Fremgangsmåde til topisk indgivelse |
| KR102614858B1 (ko) | 2016-09-22 | 2023-12-18 | 노바리크 게엠베하 | 안검염 치료에 사용되는 약제학적 조성물 |
| AU2017329983B2 (en) * | 2016-09-23 | 2022-05-05 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| CN109803650A (zh) * | 2016-09-28 | 2019-05-24 | 诺瓦利克有限责任公司 | 包含大麻素受体结合配体的组合物 |
| WO2018114557A1 (en) * | 2016-12-22 | 2018-06-28 | Novaliq Gmbh | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases |
| MX381639B (es) * | 2016-12-23 | 2025-03-13 | Novaliq Gmbh | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. |
| WO2018129364A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
| PL3612228T3 (pl) | 2017-04-21 | 2024-04-08 | Dermaliq Therapeutics, Inc. | Kompozycje jodu |
| US10717691B2 (en) | 2017-05-05 | 2020-07-21 | Novaliq Gmbh | Process for the production of semifluorinated alkanes |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| JP7814839B2 (ja) | 2017-09-27 | 2026-02-17 | ノバリック ゲーエムベーハー | 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物 |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| AU2019246035B2 (en) | 2018-03-28 | 2024-07-18 | Novaliq Gmbh | Pharmaceutical composition comprising timolol |
| JP7855312B2 (ja) | 2018-04-27 | 2026-05-08 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| EP3817743A4 (en) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE |
| EP3852734A1 (en) | 2018-09-22 | 2021-07-28 | Novaliq GmbH | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness |
| WO2020064549A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| CN113518619A (zh) * | 2019-01-21 | 2021-10-19 | 诺瓦利克有限责任公司 | 用于治疗眼部新生血管形成的药物组合物 |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| WO2020239646A1 (en) | 2019-05-24 | 2020-12-03 | Novaliq Gmbh | Ophthalmic composition for the treatment of ocular allergy |
| CN114449999A (zh) | 2019-09-06 | 2022-05-06 | 诺瓦利克有限责任公司 | 用于治疗葡萄膜炎的眼用组合物 |
| WO2021048803A1 (en) | 2019-09-13 | 2021-03-18 | Minas Coroneo | Eye drop dispenser |
| EP3861857A1 (en) * | 2020-02-07 | 2021-08-11 | Novaliq GmbH | Antiparasitic compositions |
| WO2021191273A1 (en) | 2020-03-24 | 2021-09-30 | Hovione Scientia Limited | Compositions for use in treating meibomian gland dysfunction |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| EP4606396A4 (en) * | 2022-11-11 | 2025-12-03 | Cardio Navi Medtech Wuhan Co Ltd | Coating solution for drug-coated balloons, coating material, drug-coated balloon, its preparation process and use |
| EP4665377A1 (en) * | 2023-02-13 | 2025-12-24 | Novaliq GmbH | Ophthalmic composition for ocular surgery preparation in patients with ocular surface disease |
| AU2023270196B2 (en) * | 2023-11-20 | 2025-06-26 | Dyer, Gordon Wayne DR | Method of Arthropod Egress |
| WO2026104414A1 (en) * | 2024-11-12 | 2026-05-21 | Dermaliq Therapeutics Gmbh | Topical compositions for the treatment of alopecia areata |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4839342A (en) | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
| WO1989001772A1 (en) | 1987-09-03 | 1989-03-09 | University Of Georgia Research Foundation, Inc. | Ocular cyclosporin composition |
| US5874481A (en) * | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
| DE19536504C2 (de) * | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| DE19861012A1 (de) * | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
| CZ20013769A3 (cs) * | 1999-04-30 | 2002-03-13 | Sucampo Ag | Činidlo pro léčbu suchého oka |
| DE19938668B4 (de) * | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| US20080019926A1 (en) * | 2004-04-19 | 2008-01-24 | Marie-Pierre Krafft | Lung Surfactant Supplements |
| EP1763336A1 (en) * | 2004-06-08 | 2007-03-21 | Ocularis Pharma, Inc. | Hydrophobic ophthalmic compositions and methods of use |
| DE102007055046A1 (de) * | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
| PL2110126T3 (pl) | 2008-04-18 | 2012-04-30 | Novaliq Gmbh | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
-
2009
- 2009-12-14 EP EP09015423A patent/EP2335735A1/en not_active Withdrawn
-
2010
- 2010-12-13 PT PT107907750T patent/PT2512515E/pt unknown
- 2010-12-13 KR KR1020167023214A patent/KR101722039B1/ko active Active
- 2010-12-13 CA CA2776860A patent/CA2776860C/en active Active
- 2010-12-13 JP JP2012542577A patent/JP5663595B2/ja active Active
- 2010-12-13 AU AU2010333039A patent/AU2010333039B2/en active Active
- 2010-12-13 PL PL10790775T patent/PL2512515T3/pl unknown
- 2010-12-13 US US13/513,886 patent/US8614178B2/en active Active
- 2010-12-13 CN CN201080055507.7A patent/CN102652022B/zh active Active
- 2010-12-13 ES ES10790775.0T patent/ES2449308T3/es active Active
- 2010-12-13 CA CA2941956A patent/CA2941956C/en active Active
- 2010-12-13 EP EP10790775.0A patent/EP2512515B1/en active Active
- 2010-12-13 DK DK10790775.0T patent/DK2512515T3/en active
- 2010-12-13 BR BR122020020872-4A patent/BR122020020872B1/pt active IP Right Grant
- 2010-12-13 WO PCT/EP2010/069495 patent/WO2011073134A1/en not_active Ceased
- 2010-12-13 IN IN3128DEN2012 patent/IN2012DN03128A/en unknown
- 2010-12-13 KR KR1020127018066A patent/KR101652714B1/ko active Active
- 2010-12-13 BR BR122017018955-7A patent/BR122017018955B1/pt active IP Right Grant
- 2010-12-13 MX MX2012006720A patent/MX2012006720A/es active IP Right Grant
- 2010-12-13 BR BR112012014190A patent/BR112012014190B8/pt active IP Right Grant
-
2014
- 2014-10-01 JP JP2014203406A patent/JP6096731B2/ja active Active
-
2016
- 2016-12-22 JP JP2016248533A patent/JP6397472B2/ja active Active
-
2018
- 2018-08-31 JP JP2018163569A patent/JP2019006803A/ja active Pending
- 2018-12-28 JP JP2018248700A patent/JP6731039B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012006720A (es) | Composicion farmceutica para el tratamiento de sindrome del ojo seco. | |
| MX389597B (es) | Inhibidores de cdk2/4/6 de piridopirimidinona. | |
| WO2014047427A3 (en) | Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors | |
| NZ708593A (en) | Novel pyrazole derivative | |
| MY175800A (en) | Combination treatment of cancer | |
| EP4342540A3 (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| EP4292662A3 (en) | Substituted indole mcl-1 inhibitors | |
| WO2015070224A3 (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| MX2016011468A (es) | Inhibidores de calicreína plasmática humana. | |
| DOP2019000275A (es) | Nuevos derivados de pirazol bicíclicos | |
| MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
| EP4403552A3 (en) | C-terminal hsp90-inhibitors | |
| UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| CO6602152A2 (es) | En respuesta al requerimiento de pago de reivindicaciones adicionales a las 10 primeras,presenta nuevo capítulo reivindicatorio y paga. | |
| EP3216798A3 (en) | Ketolide compounds | |
| MX341220B (es) | Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas. | |
| EP4299126A3 (en) | Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | |
| PH12013500644A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| MX2024010625A (es) | Compuestos antibioticos, metodos de fabricacion de los mismos, composiciones farmaceuticas conteniendo los mismos y usos de los mismos. | |
| CL2012003521A1 (es) | Derivado piperidino (r)-n-((r)-1-((3s-4s)-4-(4-clorofenil)-3,4-dihidroxi-3-metilpiperidin-1-il)-3-metil-1-oxobutan-2-il)-3,3-difluorociclopentanocarboxamida, modulador receptor quimiocinas; composicion farmaceutica; y uso del compuesto y su composicion en enfermedades inflamatorias y autoinmunitarias, entre otras. | |
| MX2020012989A (es) | Agente terapeutico para la fibrosis. | |
| IN2014CN02908A (enExample) | ||
| NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators |